文献速递白血病造血干细胞移植与细胞治疗

CD19靶向治疗后儿童ALL中CD19阴性极早期正常B细胞前体的相对扩增及其对MFC-MRD检测的影响

Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
PubMed 文献 · Br J Haematol · 2021-03-14

该研究分析了106例接受CD19靶向治疗(贝林妥欧单抗、CAR-T或两者)的儿童B细胞前体急性淋巴细胞白血病(BCP-ALL)患者中CD19阴性正常B细胞前体的情况。发现CD19靶向治疗后骨髓中正常CD19阴性B细胞前体较健康供者及化疗或移植后患者更常见,且其抗原表达谱可与残留白血病原始细胞混淆,即使生物信息学分析亦然。结果有助于更准确地进行MFC-MRD监测。

要点

  • CD19靶向治疗后正常CD19阴性B细胞前体可相对扩增,易与残留白血病细胞混淆。
  • MFC-MRD采用其他B系标志(CD22、CD10、CD79a等)设门时需警惕误判正常CD19阴性前体。
  • 该研究提示对CD19靶向治疗患者需更精准的MFC-MRD分析策略。

核心结论

  • CD19靶向治疗后儿童BCP-ALL骨髓中正常CD19阴性极早期B细胞前体较健康供者及化疗或移植后患者更常见,可与残留白血病原始细胞混淆。
  • 该发现有助于在CD19靶向治疗患者中更准确地进行MFC-MRD监测,即使存在正常CD19阴性B细胞前体扩增。

研究设计与样本

  • 研究总结了106例接受CD19靶向治疗的儿童BCP-ALL患者中CD19阴性正常B细胞前体的检测结果。
  • 治疗方式包括贝林妥欧单抗(n=64)、CAR-T(n=25)或两者(n=17)。

主要发现

  • CD19靶向治疗后骨髓中正常CD19阴性B细胞前体较健康供者及化疗或干细胞移植后儿童更频繁出现。
  • 抗原表达谱分析显示正常CD19阴性B细胞前体可与残留白血病原始细胞混淆,即使在MFC数据的生物信息学分析中亦然。

临床怎么用

  • 对接受CD19靶向治疗的BCP-ALL儿童进行MFC-MRD监测时,需注意正常CD19阴性极早期B细胞前体的相对扩增,避免误判为残留白血病。
  • 采用CD22、CD10、CD79a等B系标志设门识别CD19阴性白血病时,应结合抗原表达谱鉴别正常CD19阴性前体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed treatment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry (MFC) application for minimal/measurable residual disease (MRD) assessment in BCP-ALL is based on B-cell compartment study, CD19 loss could hamper MFC-MRD monitoring after blinatumomab or chimeric antigen receptor T-cell (CAR-T) therapy. The use of other antigens (CD22, CD10, CD79a, etc.) as B-lineage gating markers allows the identification of CD19-negative leukaemia, but it could also lead to misidentification of normal very-early CD19-negative BCPs as tumour blasts. In the current study, we summarized the results of the investigation of CD19-negative normal BCPs in 106 children with BCP-ALL who underwent CD19 targeting (blinatumomab, n = 64; CAR-T, n = 25; or both, n = 17). It was found that normal CD19-negative BCPs could be found in bone marrow after CD19-directed treatment more frequently than in healthy donors and children with BCP-ALL during chemotherapy or after stem cell transplantation. Analysis of the antigen expression profile revealed that normal CD19-negative BCPs could be mixed up with residual leukaemic blasts, even in bioinformatic analyses of MFC data. The results of our study should help to investigate MFC-MRD more accurately in patients who have undergone CD19-targeted therapy, even in cases with normal CD19-negative BCP expansion.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mikhailova E, Semchenkova A, Illarionova O, et al. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol. 2021. PMID: 33715150. doi:10.1111/bjh.17382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。